untitled

----

The trend toward improved treatment in emergency medicine and the use of laparoscopic procedures creates the demand for new hemostatic sealants that can be used without staples, stitches or compression. Addressing the current limitations, we have produced a novel second-generation hemostatic agent for use in military and civilian applications in emergency medicine, laparoscopic and general surgery.

ClotFoam is the first and only available technology to control high-volume hemorrhage without compression. It is the most remarkable advance in the development of hemostatic agents in the last decade. ClotFoam is designed to stop severe bleeding inmediately--no need for pressure, staples or sutures. ClotFoam polymerizes almost instantly, anchoring a strong clot over lacerated tissue.

The Future of Laparoscopic Surgery
Today, Laparoscopic surgery is becoming a suitable alternative to open surgery. Several studies of laparoscopic compared to open surgery demonstrate that large-scale application of laparoscopic surgery translates into significant savings to hospitals and health care programs, reduction in hospital stay, blood loss, postoperative pain and complications. Median post-operative hospital stay was reduced from 4.5 to 2 days. Overall hospital costs of laparoscopic procedures are significantly lower by an average of $1,300.

Bleeding in Laparoscopic Surgery
Intra-operative hemorrhage during laparoscopic procedures, remains a major risk that affects both immediate and long-term results. The control of intra-operative bleeding during laparoscopic procedures can be extremely difficult, and often results in conversion to an open approach. Available non-compressible hemostatic agents are only effective in cases of low-volume hemorrhage. Thus, easy and cost-effective homeostatic control will encourage the use of laparoscopic surgery; driven by both the clinical and social benefits of a shorter hospital stay, quicker recovery, and better cosmetic results.

----
	The trend toward improved treatment in emergency medicine and the use of laparoscopic procedures creates the demand for new hemostatic sealants that can be used without staples, stitches or compression. Addressing the current limitations, we have produced a novel second-generation hemostatic agent for use in military and civilian applications in emergency medicine, laparoscopic and general surgery. ClotFoam is the first and only available technology to control high-volume hemorrhage without compression. It is the most remarkable advance in the development of hemostatic agents in the last decade. ClotFoam is designed to stop severe bleeding inmediately--no need for pressure, staples or sutures. ClotFoam polymerizes almost instantly, anchoring a strong clot over lacerated tissue. The Future of Laparoscopic Surgery Today, Laparoscopic surgery is becoming a suitable alternative to open surgery. Several studies of laparoscopic compared to open surgery demonstrate that large-scale application of laparoscopic surgery translates into significant savings to hospitals and health care programs, reduction in hospital stay, blood loss, postoperative pain and complications. Median post-operative hospital stay was reduced from 4.5 to 2 days. Overall hospital costs of laparoscopic procedures are significantly lower by an average of $1,300. Bleeding in Laparoscopic Surgery Intra-operative hemorrhage during laparoscopic procedures, remains a major risk that affects both immediate and long-term results. The control of intra-operative bleeding during laparoscopic procedures can be extremely difficult, and often results in conversion to an open approach. Available non-compressible hemostatic agents are only effective in cases of low-volume hemorrhage. Thus, easy and cost-effective homeostatic control will encourage the use of laparoscopic surgery; driven by both the clinical and social benefits of a shorter hospital stay, quicker recovery, and better cosmetic results.